Abstract number: DI-067 ATC code: G04 – Urologicals



RETROSPECTIVE STUDY OF ALFUZOSIN 10mg PRESCRIPTIONS


C. PHILIP, A. GLANARD., R. GERVAIS







Background

Alfuzosin is indicated for the treatment of the symptoms of benign prostatic hyperplasia (BPH) and as adjunctive therapy with ureteral catheterization for acute urinary retention related to BPH. The alpha-blocking properties on the urinary tract are used for various indications not mentioned in the marketing authorization (MA) for men et women.









Renal and hepatic functions:

33 patients suffered from severe renal failure, nobody of severe hepatic failure which are contraindicated according to the summary of characteristics product.



*acute urinary retention related to kidney stone, obstructive pyelonephritis, prostatitis, hypoactive bladder due to the use of a neuroleptic...


**neurogenic bladder in connection with stroke, Parkinson's disease, multiple sclerosis...



Among these interactions, 85% concerned elderly people. A population particularly concerned by the risk of falling.



The intake at bedtime and not in the morning is a factor allowing to reduce this risk of falls. More than 85% of prescriptions mentioned an evening administration including 100% in geriatric services.



Conclusion

Our study revealed various off-label indications, all developed in several scientific papers and underlined the issue of drug-related iatrogenia among the elderly. The improvement process of medicinal treatment has led us to write a summary (for medical and pharmacy interns) of the indications mentioned or not in the MA and the recommendations linked to the prescription. Another analysis will be done in one year.